
Cellectis Investor Relations Material
Latest events

Q3 2024
Cellectis
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Cellectis S.A.
Access all reports
Cellectis is a clinical stage biotechnological company, developing immuno-oncology products based on gene-edited T-cells. According to Cellectis, it is one of the very few companies capable of generating next generation T-cell product candidates in an entirely novel approach. By combining the full functionality of T-cells with the specificity provided by artificial antigen receptors (chimeric antigen receptors), their program aims at achieving superior antiviral, anti-tumor and anti-inflammatory potential.
Key slides for Cellectis S.A.


Corporate Presentation
Cellectis S.A.


Corporate Presentation
Cellectis S.A.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
ALCLS
Country
🇫🇷 France